Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
SightGlass Vision, Inc. · NCT07229352
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 6–12 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 20
- US sites recruiting
- 1
- Study start
- February 2, 2026
- Record last updated
- April 30, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).
Being studied: Novel spectacle lens design; Spectacle lenses
Conditions: Myopia; Myopia Progression; Juvenile Myopia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
A participant is eligible for inclusion in the study if they meet the following criteria:
- Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
- Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
- Have undergone a self-reported oculo-visual examination within the past two years.
- Have no active ocular disease.
- Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
- Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
- The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
Exclusion Criteria
A participant will be excluded from the study if they meet any of the following conditions:
- Have any systemic disease that affects ocular health.
- Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
- Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
- Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
- Have known developmental delays.
- Have participated in another clinical study in the last 7 days
Recruiting US locations
Midwestern University Arizona College of Optometry
Glendale, AZ 85308
Site contact: Javier Gantes-Nunez
Study contacts (from the official record)
- Jennifer Hill · 6783614877 · jhill@sightglassvision.com
Similar studies in Arizona
All healthy volunteers studies in Arizona →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Location
- Phoenix, AZ
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
AstraZeneca
- Location
- Chandler, AZ + 2 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingHealthy volunteersPhase 1
A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
Vertex Pharmaceuticals Incorporated
- Location
- Tempe, AZ
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingHealthy volunteersPhase 1
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
Epygenix
- Location
- Tempe, AZ
- Eligibility basics
- Ages 18–55